Notice of Correction to Application Due Dates in PAR-22-049 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)"
Notice Number:
NOT-CA-23-054

Key Dates

Release Date:

March, 29 2023

Related Announcements

PAR-22-049 - Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

This Notice corrects the matrix of Application Due Dates for PAR-22-049 "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)".

The following section of PAR-22-049 has been corrected:

Part 1. Overview Information, Key Dates

Currently, it reads:

Application Due DatesReview and Award Cycles
NewRenewal / Resubmission / Revision (as allowed)AIDSScientific Merit ReviewAdvisory Council ReviewEarliest Start Date
January 11, 2022January 11, 2022Not ApplicableJuly 2022October 2022December 2022
June 07, 2022June 07, 2022Not ApplicableNovember 2022January 2023April 2023
September 13, 2022September 13, 2022Not ApplicableMarch 2023May 2023July 2023
January 11, 2023March 05, 2023 *Not ApplicableJuly 2023October 2023December 2023
June 07, 2023June 07, 2023Not ApplicableNovember 2023January 2024April 2024
September 13, 2023September 13, 2023Not ApplicableMarch 2024May 2024July 2024
January 11, 2024March 05, 2024 *Not ApplicableJuly 2024October 2024December 2024
June 07, 2024June 07, 2024Not ApplicableNovember 2024January 2025April 2025
September 13, 2024September 13, 2024Not ApplicableMarch 2025May 2025July 2025

Corrected to read (in bold italics):

Application Due DatesReview and Award Cycles
NewRenewal / Resubmission / Revision (as allowed)AIDSScientific Merit ReviewAdvisory Council ReviewEarliest Start Date
January 11, 2022January 11, 2022Not ApplicableJuly 2022October 2022December 2022
June 07, 2022June 07, 2022Not ApplicableNovember 2022January 2023April 2023
September 13, 2022September 13, 2022Not ApplicableMarch 2023May 2023July 2023
January 11, 2023March 05, 2023 *Not ApplicableJuly 2023October 2023December 2023
June 07, 2023June 07, 2023Not ApplicableNovember 2023January 2024April 2024
September 13, 2023September 13, 2023Not ApplicableMarch 2024May 2024July 2024
January 11, 2024January 11. 2024Not ApplicableJuly 2024October 2024December 2024
June 07, 2024June 07, 2024Not ApplicableNovember 2024January 2025April 2025
September 13, 2024September 13, 2024Not ApplicableMarch 2025May 2025July 2025

All other aspects of PAR-22-049 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Lokesh Agrawal, PhD
National Cancer Institute (NCI)
Telephone:240-276-5718
Email: lokesh.agrawal@nih.gov

Abhi Rao, PhD
National Cancer Institute (NCI)
Telephone: 240-276-5715
Email: abhi.rao@nih.gov

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: ncirefof@dea.nci.nih.gov

Financial/Grants Management Contact(s)

Shane Woodward
National Cancer Institute (NCI)
Telephone: 240-276-6303
Email: Shane.Woodward@nih.gov

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.